Cardlytics, Inc. (NASDAQ:CDLX) Receives Average Recommendation of “Hold” from Analysts

Cardlytics, Inc. (NASDAQ:CDLX) has earned an average recommendation of “Hold” from the seven research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.92.

A number of equities analysts have weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI assumed coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. Craig Hallum raised Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Northland Securities downgraded Cardlytics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $7.00 to $5.00 in a research report on Friday, August 16th. Finally, Northland Capmk downgraded Cardlytics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 16th.

Insider Transactions at Cardlytics

In other news, CFO Alexis Desieno sold 25,118 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the transaction, the chief financial officer now directly owns 116,481 shares of the company’s stock, valued at $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Amit Gupta sold 22,607 shares of Cardlytics stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at $687,298.15. The trade was a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,691 shares of company stock worth $237,767 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

Hedge funds have recently bought and sold shares of the stock. Sanctuary Advisors LLC bought a new position in shares of Cardlytics during the third quarter worth approximately $82,000. Barclays PLC lifted its holdings in shares of Cardlytics by 223.9% during the third quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after buying an additional 40,112 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Cardlytics in the third quarter valued at about $63,000. Finally, RBF Capital LLC increased its position in Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock worth $1,562,000 after acquiring an additional 369,620 shares during the period. 68.10% of the stock is currently owned by institutional investors and hedge funds.

Cardlytics Price Performance

Shares of CDLX opened at $4.05 on Wednesday. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a 50 day simple moving average of $3.86 and a 200 day simple moving average of $5.50. Cardlytics has a 52-week low of $2.89 and a 52-week high of $20.52. The firm has a market capitalization of $205.82 million, a PE ratio of -0.66 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business had revenue of $67.06 million during the quarter, compared to analyst estimates of $57.77 million. During the same period in the previous year, the firm earned ($0.26) EPS. Cardlytics’s quarterly revenue was down 15.1% compared to the same quarter last year. Sell-side analysts predict that Cardlytics will post -1.52 EPS for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.